You are here: Industry Insights > small molecule

News List

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
Block-buster Small Molecule Pharmaceuticals Approved by the NMPA in 2023 Yefenghong
March 06, 2024
According to data collated from the National Medical Products Administration (NMPA) official website, a total of more than 80 new drugs were granted inaugural approval within the domestic market.
Breakthrough in Research of Small Molecule Drugs against SARS-CoV-2 PharmaSources/Xiaonisha
March 21, 2022
Corona virus disease 2019 (COVID-19) caused by a novel single-stranded RNA coronavirus has swept the world. The International Committee on Taxonomy of Viruses (ICTV) named the virus SARS-CoV-2.
Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released PharmaSources/Xiaoyaowan
December 02, 2021
Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer.
Small Molecule and Great Potential: Oral Small Molecule COVID-19 Pharmaceutical Chemicals PharmaSources/Xiaoyaowan
October 28, 2021
Recently, MSD announced to initiate the Phase III clinical trial of its oral small molecule COVID-19 drug - Molnupiravir (MK-4482).
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update PharmaSources
January 22, 2025
Ascletis announces positive topline results from its U.S. SAD study of ASC30 oral tablet in obese patients, showing good PK, safety and potential for best - in - class status.
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics WorldPharmaNews
January 13, 2022
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors prnasia
January 10, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 AmericanPharmaceuticalReview
December 09, 2021
Sosei Group Corporation announced it has received grant funding from Wellcome, through the COVID-19 Therapeutics Accelerator. The funding will be used to advance the pre-clinical development of the Company's novel oral anti-viral small molecules ...
Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI prnasia
August 05, 2021
Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperation in advancing the development of novel therapies.